id	sid	tid	token	lemma	pos
cord-308293-8y2iaqnl	1	1	key	key	NN
cord-308293-8y2iaqnl	1	2	:	:	:
cord-308293-8y2iaqnl	2	1	cord-308293	cord-308293	NNP
cord-308293-8y2iaqnl	2	2	-	-	HYPH
cord-308293-8y2iaqnl	2	3	8y2iaqnl	8y2iaqnl	CD
cord-308293-8y2iaqnl	2	4	authors	author	NNS
cord-308293-8y2iaqnl	2	5	:	:	:
cord-308293-8y2iaqnl	2	6	Singh	Singh	NNP
cord-308293-8y2iaqnl	2	7	,	,	,
cord-308293-8y2iaqnl	2	8	Vijay	Vijay	NNP
cord-308293-8y2iaqnl	2	9	P.	P.	NNP
cord-308293-8y2iaqnl	2	10	;	;	:
cord-308293-8y2iaqnl	2	11	El	El	NNP
cord-308293-8y2iaqnl	2	12	-	-	HYPH
cord-308293-8y2iaqnl	2	13	Kurdi	Kurdi	NNP
cord-308293-8y2iaqnl	2	14	,	,	,
cord-308293-8y2iaqnl	2	15	Bara	Bara	NNP
cord-308293-8y2iaqnl	2	16	;	;	:
cord-308293-8y2iaqnl	2	17	Rood	Rood	NNP
cord-308293-8y2iaqnl	2	18	,	,	,
cord-308293-8y2iaqnl	2	19	Christopher	Christopher	NNP
cord-308293-8y2iaqnl	2	20	title	title	NN
cord-308293-8y2iaqnl	2	21	:	:	:
cord-308293-8y2iaqnl	3	1	What	what	WP
cord-308293-8y2iaqnl	3	2	underlies	underlie	VBZ
cord-308293-8y2iaqnl	3	3	the	the	DT
cord-308293-8y2iaqnl	3	4	benefit	benefit	NN
cord-308293-8y2iaqnl	3	5	of	of	IN
cord-308293-8y2iaqnl	3	6	famotidine	famotidine	NN
cord-308293-8y2iaqnl	3	7	formulations	formulation	NNS
cord-308293-8y2iaqnl	3	8	used	use	VBN
cord-308293-8y2iaqnl	3	9	during	during	IN
cord-308293-8y2iaqnl	3	10	COVID-19	COVID-19	NNP
cord-308293-8y2iaqnl	3	11	?	?	.
cord-308293-8y2iaqnl	3	12	date	date	NN
cord-308293-8y2iaqnl	3	13	:	:	:
cord-308293-8y2iaqnl	3	14	2020	2020	CD
cord-308293-8y2iaqnl	3	15	-	-	HYPH
cord-308293-8y2iaqnl	3	16	08	08	CD
cord-308293-8y2iaqnl	3	17	-	-	HYPH
cord-308293-8y2iaqnl	3	18	07	07	CD
cord-308293-8y2iaqnl	3	19	journal	journal	NN
cord-308293-8y2iaqnl	3	20	:	:	:
cord-308293-8y2iaqnl	4	1	Gastroenterology	Gastroenterology	NNP
cord-308293-8y2iaqnl	4	2	DOI	DOI	NNP
cord-308293-8y2iaqnl	4	3	:	:	:
cord-308293-8y2iaqnl	4	4	10.1053	10.1053	CD
cord-308293-8y2iaqnl	4	5	/	/	SYM
cord-308293-8y2iaqnl	4	6	j.gastro.2020.07.051	j.gastro.2020.07.051	CD
cord-308293-8y2iaqnl	4	7	sha	sha	NN
cord-308293-8y2iaqnl	4	8	:	:	:
cord-308293-8y2iaqnl	4	9	99601d300942a5f4d8d326f85284bd8e6c341f9d	99601d300942a5f4d8d326f85284bd8e6c341f9d	CD
cord-308293-8y2iaqnl	4	10	doc_id	doc_id	CD
cord-308293-8y2iaqnl	4	11	:	:	:
cord-308293-8y2iaqnl	4	12	308293	308293	CD
cord-308293-8y2iaqnl	4	13	cord_uid	cord_uid	FW
cord-308293-8y2iaqnl	4	14	:	:	:
cord-308293-8y2iaqnl	5	1	8y2iaqnl	8y2iaqnl	NNP
cord-308293-8y2iaqnl	6	1	nan	nan	NNP
cord-308293-8y2iaqnl	7	1	This	this	DT
cord-308293-8y2iaqnl	7	2	letter	letter	NN
cord-308293-8y2iaqnl	7	3	is	be	VBZ
cord-308293-8y2iaqnl	7	4	in	in	IN
cord-308293-8y2iaqnl	7	5	reference	reference	NN
cord-308293-8y2iaqnl	7	6	to	to	IN
cord-308293-8y2iaqnl	7	7	the	the	DT
cord-308293-8y2iaqnl	7	8	study	study	NN
cord-308293-8y2iaqnl	7	9	by	by	IN
cord-308293-8y2iaqnl	7	10	Freedberg	Freedberg	NNP
cord-308293-8y2iaqnl	7	11	et	et	NNP
cord-308293-8y2iaqnl	7	12	al	al	NNP
cord-308293-8y2iaqnl	7	13	1	1	CD
cord-308293-8y2iaqnl	7	14	 	 	_SP
cord-308293-8y2iaqnl	8	1	This	this	DT
cord-308293-8y2iaqnl	8	2	was	be	VBD
cord-308293-8y2iaqnl	8	3	a	a	DT
cord-308293-8y2iaqnl	8	4	retrospective	retrospective	JJ
cord-308293-8y2iaqnl	8	5	analysis	analysis	NN
cord-308293-8y2iaqnl	8	6	of	of	IN
cord-308293-8y2iaqnl	8	7	an	an	DT
cord-308293-8y2iaqnl	8	8	inpatient	inpatient	JJ
cord-308293-8y2iaqnl	8	9	cohort	cohort	NN
cord-308293-8y2iaqnl	8	10	admitted	admit	VBD
cord-308293-8y2iaqnl	8	11	to	to	IN
cord-308293-8y2iaqnl	8	12	two	two	CD
cord-308293-8y2iaqnl	8	13	hospitals	hospital	NNS
cord-308293-8y2iaqnl	8	14	in	in	IN
cord-308293-8y2iaqnl	8	15	New	New	NNP
cord-308293-8y2iaqnl	8	16	York	York	NNP
cord-308293-8y2iaqnl	8	17	,	,	,
cord-308293-8y2iaqnl	8	18	which	which	WDT
cord-308293-8y2iaqnl	8	19	found	find	VBD
cord-308293-8y2iaqnl	8	20	that	that	IN
cord-308293-8y2iaqnl	8	21	COVID-19	covid-19	CD
cord-308293-8y2iaqnl	8	22	patients	patient	NNS
cord-308293-8y2iaqnl	8	23	who	who	WP
cord-308293-8y2iaqnl	8	24	were	be	VBD
cord-308293-8y2iaqnl	8	25	treated	treat	VBN
cord-308293-8y2iaqnl	8	26	with	with	IN
cord-308293-8y2iaqnl	8	27	famotidine	famotidine	NNP
cord-308293-8y2iaqnl	8	28	exhibited	exhibit	VBD
cord-308293-8y2iaqnl	8	29	a	a	DT
cord-308293-8y2iaqnl	8	30	lower	low	JJR
cord-308293-8y2iaqnl	8	31	risk	risk	NN
cord-308293-8y2iaqnl	8	32	of	of	IN
cord-308293-8y2iaqnl	8	33	death	death	NN
cord-308293-8y2iaqnl	8	34	or	or	CC
cord-308293-8y2iaqnl	8	35	mechanical	mechanical	JJ
cord-308293-8y2iaqnl	8	36	ventilation	ventilation	NN
cord-308293-8y2iaqnl	8	37	as	as	IN
cord-308293-8y2iaqnl	8	38	composite	composite	JJ
cord-308293-8y2iaqnl	8	39	outcomes	outcome	NNS
cord-308293-8y2iaqnl	8	40	over	over	IN
cord-308293-8y2iaqnl	8	41	a	a	DT
cord-308293-8y2iaqnl	8	42	30-day	30-day	CD
cord-308293-8y2iaqnl	8	43	period	period	NN
cord-308293-8y2iaqnl	8	44	.	.	.
cord-308293-8y2iaqnl	9	1	The	the	DT
cord-308293-8y2iaqnl	9	2	study	study	NN
cord-308293-8y2iaqnl	9	3	was	be	VBD
cord-308293-8y2iaqnl	9	4	based	base	VBN
cord-308293-8y2iaqnl	9	5	on	on	IN
cord-308293-8y2iaqnl	9	6	computational	computational	JJ
cord-308293-8y2iaqnl	9	7	modelling	modelling	NN
cord-308293-8y2iaqnl	9	8	,	,	,
cord-308293-8y2iaqnl	9	9	which	which	WDT
cord-308293-8y2iaqnl	9	10	proposed	propose	VBD
cord-308293-8y2iaqnl	9	11	famotidine	famotidine	NNP
cord-308293-8y2iaqnl	9	12	might	may	MD
cord-308293-8y2iaqnl	9	13	inhibit	inhibit	VB
cord-308293-8y2iaqnl	9	14	viral	viral	JJ
cord-308293-8y2iaqnl	9	15	replication	replication	NN
cord-308293-8y2iaqnl	9	16	through	through	IN
cord-308293-8y2iaqnl	9	17	direct	direct	JJ
cord-308293-8y2iaqnl	9	18	interaction	interaction	NN
cord-308293-8y2iaqnl	9	19	with	with	IN
cord-308293-8y2iaqnl	9	20	the	the	DT
cord-308293-8y2iaqnl	9	21	3-chymotrypsin	3-chymotrypsin	CD
cord-308293-8y2iaqnl	9	22	-	-	HYPH
cord-308293-8y2iaqnl	9	23	like	like	JJ
cord-308293-8y2iaqnl	9	24	protease	protease	NN
cord-308293-8y2iaqnl	9	25	2	2	CD
cord-308293-8y2iaqnl	9	26	,	,	,
cord-308293-8y2iaqnl	9	27	and	and	CC
cord-308293-8y2iaqnl	9	28	was	be	VBD
cord-308293-8y2iaqnl	9	29	also	also	RB
cord-308293-8y2iaqnl	9	30	preceded	precede	VBN
cord-308293-8y2iaqnl	9	31	by	by	IN
cord-308293-8y2iaqnl	9	32	a	a	DT
cord-308293-8y2iaqnl	9	33	small	small	JJ
cord-308293-8y2iaqnl	9	34	,	,	,
cord-308293-8y2iaqnl	9	35	short	short	JJ
cord-308293-8y2iaqnl	9	36	-	-	HYPH
cord-308293-8y2iaqnl	9	37	term	term	NN
cord-308293-8y2iaqnl	9	38	follow	follow	NN
cord-308293-8y2iaqnl	9	39	-	-	HYPH
cord-308293-8y2iaqnl	9	40	up	up	NN
cord-308293-8y2iaqnl	9	41	,	,	,
cord-308293-8y2iaqnl	9	42	outpatient	outpatient	NN
cord-308293-8y2iaqnl	9	43	study	study	NN
cord-308293-8y2iaqnl	9	44	suggesting	suggest	VBG
cord-308293-8y2iaqnl	9	45	that	that	IN
cord-308293-8y2iaqnl	9	46	famotidine	famotidine	NNP
cord-308293-8y2iaqnl	9	47	use	use	NN
cord-308293-8y2iaqnl	9	48	was	be	VBD
cord-308293-8y2iaqnl	9	49	associated	associate	VBN
cord-308293-8y2iaqnl	9	50	with	with	IN
cord-308293-8y2iaqnl	9	51	symptomatic	symptomatic	JJ
cord-308293-8y2iaqnl	9	52	improvement	improvement	NN
cord-308293-8y2iaqnl	9	53	3	3	CD
cord-308293-8y2iaqnl	9	54	.	.	.
cord-308293-8y2iaqnl	10	1	However	however	RB
cord-308293-8y2iaqnl	10	2	,	,	,
cord-308293-8y2iaqnl	10	3	the	the	DT
cord-308293-8y2iaqnl	10	4	current	current	JJ
cord-308293-8y2iaqnl	10	5	study	study	NN
cord-308293-8y2iaqnl	10	6	published	publish	VBN
cord-308293-8y2iaqnl	10	7	in	in	IN
cord-308293-8y2iaqnl	10	8	Gastroenterology	Gastroenterology	NNP
cord-308293-8y2iaqnl	10	9	provides	provide	VBZ
cord-308293-8y2iaqnl	10	10	additional	additional	JJ
cord-308293-8y2iaqnl	10	11	value	value	NN
cord-308293-8y2iaqnl	10	12	as	as	IN
cord-308293-8y2iaqnl	10	13	the	the	DT
cord-308293-8y2iaqnl	10	14	previous	previous	JJ
cord-308293-8y2iaqnl	10	15	cohort	cohort	NN
cord-308293-8y2iaqnl	10	16	was	be	VBD
cord-308293-8y2iaqnl	10	17	much	much	RB
cord-308293-8y2iaqnl	10	18	smaller	small	JJR
cord-308293-8y2iaqnl	10	19	in	in	IN
cord-308293-8y2iaqnl	10	20	number	number	NN
cord-308293-8y2iaqnl	10	21	,	,	,
cord-308293-8y2iaqnl	10	22	included	include	VBD
cord-308293-8y2iaqnl	10	23	patients	patient	NNS
cord-308293-8y2iaqnl	10	24	without	without	IN
cord-308293-8y2iaqnl	10	25	a	a	DT
cord-308293-8y2iaqnl	10	26	proven	prove	VBN
cord-308293-8y2iaqnl	10	27	COVID-19	covid-19	JJ
cord-308293-8y2iaqnl	10	28	diagnosis	diagnosis	NN
cord-308293-8y2iaqnl	10	29	,	,	,
cord-308293-8y2iaqnl	10	30	and	and	CC
cord-308293-8y2iaqnl	10	31	lacked	lack	VBD
cord-308293-8y2iaqnl	10	32	a	a	DT
cord-308293-8y2iaqnl	10	33	control	control	NN
cord-308293-8y2iaqnl	10	34	group	group	NN
cord-308293-8y2iaqnl	10	35	.	.	.
cord-308293-8y2iaqnl	11	1	The	the	DT
cord-308293-8y2iaqnl	11	2	current	current	JJ
cord-308293-8y2iaqnl	11	3	study	study	NN
cord-308293-8y2iaqnl	11	4	by	by	IN
cord-308293-8y2iaqnl	11	5	Freedberg	Freedberg	NNP
cord-308293-8y2iaqnl	11	6	et	et	NNP
cord-308293-8y2iaqnl	11	7	al	al	NNP
cord-308293-8y2iaqnl	11	8	1	1	CD
cord-308293-8y2iaqnl	11	9	brings	bring	VBZ
cord-308293-8y2iaqnl	11	10	a	a	DT
cord-308293-8y2iaqnl	11	11	few	few	JJ
cord-308293-8y2iaqnl	11	12	questions	question	NNS
cord-308293-8y2iaqnl	11	13	to	to	TO
cord-308293-8y2iaqnl	11	14	mind	mind	VB
cord-308293-8y2iaqnl	11	15	,	,	,
cord-308293-8y2iaqnl	11	16	which	which	WDT
cord-308293-8y2iaqnl	11	17	we	-PRON-	PRP
cord-308293-8y2iaqnl	11	18	hope	hope	VBP
cord-308293-8y2iaqnl	11	19	the	the	DT
cord-308293-8y2iaqnl	11	20	authors	author	NNS
cord-308293-8y2iaqnl	11	21	can	can	MD
cord-308293-8y2iaqnl	11	22	answer	answer	VB
cord-308293-8y2iaqnl	11	23	.	.	.
cord-308293-8y2iaqnl	12	1	In	in	IN
cord-308293-8y2iaqnl	12	2	the	the	DT
cord-308293-8y2iaqnl	12	3	conclusions	conclusion	NNS
cord-308293-8y2iaqnl	12	4	,	,	,
cord-308293-8y2iaqnl	12	5	the	the	DT
cord-308293-8y2iaqnl	12	6	authors	author	NNS
cord-308293-8y2iaqnl	12	7	stated	state	VBD
cord-308293-8y2iaqnl	12	8	,	,	,
cord-308293-8y2iaqnl	12	9	"	"	``
cord-308293-8y2iaqnl	12	10	The	the	DT
cord-308293-8y2iaqnl	12	11	study	study	NN
cord-308293-8y2iaqnl	12	12	was	be	VBD
cord-308293-8y2iaqnl	12	13	premised	premise	VBN
cord-308293-8y2iaqnl	12	14	on	on	IN
cord-308293-8y2iaqnl	12	15	the	the	DT
cord-308293-8y2iaqnl	12	16	assumption	assumption	NN
cord-308293-8y2iaqnl	12	17	that	that	IN
cord-308293-8y2iaqnl	12	18	use	use	NN
cord-308293-8y2iaqnl	12	19	of	of	IN
cord-308293-8y2iaqnl	12	20	famotidine	famotidine	NN
cord-308293-8y2iaqnl	12	21	represented	represent	VBD
cord-308293-8y2iaqnl	12	22	a	a	DT
cord-308293-8y2iaqnl	12	23	continuation	continuation	NN
cord-308293-8y2iaqnl	12	24	of	of	IN
cord-308293-8y2iaqnl	12	25	home	home	NN
cord-308293-8y2iaqnl	12	26	use	use	NN
cord-308293-8y2iaqnl	12	27	"	"	''
cord-308293-8y2iaqnl	12	28	.	.	.
cord-308293-8y2iaqnl	13	1	In	in	IN
cord-308293-8y2iaqnl	13	2	the	the	DT
cord-308293-8y2iaqnl	13	3	results	result	NNS
cord-308293-8y2iaqnl	13	4	section	section	NN
cord-308293-8y2iaqnl	13	5	they	-PRON-	PRP
cord-308293-8y2iaqnl	13	6	also	also	RB
cord-308293-8y2iaqnl	13	7	say	say	VBP
cord-308293-8y2iaqnl	13	8	"	"	``
cord-308293-8y2iaqnl	13	9	Home	home	NN
cord-308293-8y2iaqnl	13	10	use	use	NN
cord-308293-8y2iaqnl	13	11	of	of	IN
cord-308293-8y2iaqnl	13	12	famotidine	famotidine	NN
cord-308293-8y2iaqnl	13	13	was	be	VBD
cord-308293-8y2iaqnl	13	14	documented	document	VBN
cord-308293-8y2iaqnl	13	15	on	on	IN
cord-308293-8y2iaqnl	13	16	admission	admission	NN
cord-308293-8y2iaqnl	13	17	medication	medication	NN
cord-308293-8y2iaqnl	13	18	reconciliation	reconciliation	NN
cord-308293-8y2iaqnl	13	19	in	in	IN
cord-308293-8y2iaqnl	13	20	15	15	CD
cord-308293-8y2iaqnl	13	21	%	%	NN
cord-308293-8y2iaqnl	13	22	of	of	IN
cord-308293-8y2iaqnl	13	23	those	those	DT
cord-308293-8y2iaqnl	13	24	who	who	WP
cord-308293-8y2iaqnl	13	25	used	use	VBD
cord-308293-8y2iaqnl	13	26	famotidine	famotidine	NN
cord-308293-8y2iaqnl	13	27	while	while	IN
cord-308293-8y2iaqnl	13	28	hospitalized	hospitalize	VBN
cord-308293-8y2iaqnl	13	29	"	"	''
cord-308293-8y2iaqnl	13	30	.	.	.
cord-308293-8y2iaqnl	14	1	These	these	DT
cord-308293-8y2iaqnl	14	2	bring	bring	VBP
cord-308293-8y2iaqnl	14	3	up	up	RP
cord-308293-8y2iaqnl	14	4	a	a	DT
cord-308293-8y2iaqnl	14	5	few	few	JJ
cord-308293-8y2iaqnl	14	6	questions	question	NNS
cord-308293-8y2iaqnl	14	7	:	:	:
cord-308293-8y2iaqnl	14	8	1	1	LS
cord-308293-8y2iaqnl	14	9	)	)	-RRB-
cord-308293-8y2iaqnl	14	10	Does	do	VBZ
cord-308293-8y2iaqnl	14	11	this	this	DT
cord-308293-8y2iaqnl	14	12	indicate	indicate	VB
cord-308293-8y2iaqnl	14	13	that	that	IN
cord-308293-8y2iaqnl	14	14	the	the	DT
cord-308293-8y2iaqnl	14	15	remaining	remain	VBG
cord-308293-8y2iaqnl	14	16	85	85	CD
cord-308293-8y2iaqnl	14	17	%	%	NN
cord-308293-8y2iaqnl	14	18	patients	patient	NNS
cord-308293-8y2iaqnl	14	19	given	give	VBN
cord-308293-8y2iaqnl	14	20	famotidine	famotidine	NN
cord-308293-8y2iaqnl	14	21	during	during	IN
cord-308293-8y2iaqnl	14	22	hospitalization	hospitalization	NN
cord-308293-8y2iaqnl	14	23	were	be	VBD
cord-308293-8y2iaqnl	14	24	using	use	VBG
cord-308293-8y2iaqnl	14	25	over	over	IN
cord-308293-8y2iaqnl	14	26	the	the	DT
cord-308293-8y2iaqnl	14	27	counter	counter	NN
cord-308293-8y2iaqnl	14	28	formulations	formulation	NNS
cord-308293-8y2iaqnl	14	29	at	at	IN
cord-308293-8y2iaqnl	14	30	home	home	NN
cord-308293-8y2iaqnl	14	31	which	which	WDT
cord-308293-8y2iaqnl	14	32	were	be	VBD
cord-308293-8y2iaqnl	14	33	not	not	RB
cord-308293-8y2iaqnl	14	34	prescribed	prescribe	VBN
cord-308293-8y2iaqnl	14	35	by	by	IN
cord-308293-8y2iaqnl	14	36	a	a	DT
cord-308293-8y2iaqnl	14	37	physician	physician	NN
cord-308293-8y2iaqnl	14	38	?	?	.
cord-308293-8y2iaqnl	15	1	2	2	LS
cord-308293-8y2iaqnl	15	2	)	)	-RRB-
cord-308293-8y2iaqnl	15	3	Were	be	VBD
cord-308293-8y2iaqnl	15	4	these	these	DT
cord-308293-8y2iaqnl	15	5	formulations	formulation	NNS
cord-308293-8y2iaqnl	15	6	continued	continue	VBD
cord-308293-8y2iaqnl	15	7	in	in	IN
cord-308293-8y2iaqnl	15	8	-	-	HYPH
cord-308293-8y2iaqnl	15	9	patient	patient	NN
cord-308293-8y2iaqnl	15	10	?	?	.
cord-308293-8y2iaqnl	16	1	3	3	LS
cord-308293-8y2iaqnl	16	2	)	)	-RRB-
cord-308293-8y2iaqnl	17	1	What	what	WP
cord-308293-8y2iaqnl	17	2	were	be	VBD
cord-308293-8y2iaqnl	17	3	the	the	DT
cord-308293-8y2iaqnl	17	4	formulations	formulation	NNS
cord-308293-8y2iaqnl	17	5	of	of	IN
cord-308293-8y2iaqnl	17	6	famotidine	famotidine	NN
cord-308293-8y2iaqnl	17	7	used	use	VBN
cord-308293-8y2iaqnl	17	8	by	by	IN
cord-308293-8y2iaqnl	17	9	the	the	DT
cord-308293-8y2iaqnl	17	10	hospital	hospital	NN
cord-308293-8y2iaqnl	17	11	pharmacies	pharmacy	NNS
cord-308293-8y2iaqnl	17	12	?	?	.
cord-308293-8y2iaqnl	18	1	4	4	LS
cord-308293-8y2iaqnl	18	2	)	)	-RRB-
cord-308293-8y2iaqnl	19	1	Did	do	VBD
cord-308293-8y2iaqnl	19	2	some	some	DT
cord-308293-8y2iaqnl	19	3	included	include	VBN
cord-308293-8y2iaqnl	19	4	patients	patient	NNS
cord-308293-8y2iaqnl	19	5	receive	receive	VB
cord-308293-8y2iaqnl	19	6	concomitant	concomitant	JJ
cord-308293-8y2iaqnl	19	7	treatment	treatment	NN
cord-308293-8y2iaqnl	19	8	with	with	IN
cord-308293-8y2iaqnl	19	9	antacids	antacid	NNS
cord-308293-8y2iaqnl	19	10	,	,	,
cord-308293-8y2iaqnl	19	11	particularly	particularly	RB
cord-308293-8y2iaqnl	19	12	calcium	calcium	NN
cord-308293-8y2iaqnl	19	13	-	-	HYPH
cord-308293-8y2iaqnl	19	14	containing	contain	VBG
cord-308293-8y2iaqnl	19	15	compounds	compound	NNS
cord-308293-8y2iaqnl	19	16	?	?	.
cord-308293-8y2iaqnl	20	1	5	5	LS
cord-308293-8y2iaqnl	20	2	)	)	-RRB-
cord-308293-8y2iaqnl	21	1	It	-PRON-	PRP
cord-308293-8y2iaqnl	21	2	is	be	VBZ
cord-308293-8y2iaqnl	21	3	also	also	RB
cord-308293-8y2iaqnl	21	4	mentioned	mention	VBN
cord-308293-8y2iaqnl	21	5	that	that	IN
cord-308293-8y2iaqnl	21	6	28	28	CD
cord-308293-8y2iaqnl	21	7	%	%	NN
cord-308293-8y2iaqnl	21	8	hospitalized	hospitalize	VBD
cord-308293-8y2iaqnl	21	9	COVID-19	COVID-19	,
cord-308293-8y2iaqnl	21	10	patients	patient	NNS
cord-308293-8y2iaqnl	21	11	received	receive	VBD
cord-308293-8y2iaqnl	21	12	famotidine	famotidine	NNP
cord-308293-8y2iaqnl	21	13	intravenously	intravenously	RB
cord-308293-8y2iaqnl	21	14	.	.	.
cord-308293-8y2iaqnl	22	1	Was	be	VBD
cord-308293-8y2iaqnl	22	2	there	there	EX
cord-308293-8y2iaqnl	22	3	a	a	DT
cord-308293-8y2iaqnl	22	4	difference	difference	NN
cord-308293-8y2iaqnl	22	5	in	in	IN
cord-308293-8y2iaqnl	22	6	outcomes	outcome	NNS
cord-308293-8y2iaqnl	22	7	between	between	IN
cord-308293-8y2iaqnl	22	8	the	the	DT
cord-308293-8y2iaqnl	22	9	intravenously	intravenously	RB
cord-308293-8y2iaqnl	22	10	treated	treat	VBN
cord-308293-8y2iaqnl	22	11	group	group	NN
cord-308293-8y2iaqnl	22	12	and	and	CC
cord-308293-8y2iaqnl	22	13	the	the	DT
cord-308293-8y2iaqnl	22	14	orally	orally	RB
cord-308293-8y2iaqnl	22	15	treated	treat	VBN
cord-308293-8y2iaqnl	22	16	group	group	NN
cord-308293-8y2iaqnl	22	17	?	?	.
cord-308293-8y2iaqnl	23	1	We	-PRON-	PRP
cord-308293-8y2iaqnl	23	2	ask	ask	VBP
cord-308293-8y2iaqnl	23	3	since	since	IN
cord-308293-8y2iaqnl	23	4	popular	popular	JJ
cord-308293-8y2iaqnl	23	5	over	over	IN
cord-308293-8y2iaqnl	23	6	the	the	DT
cord-308293-8y2iaqnl	23	7	counter	counter	JJ
cord-308293-8y2iaqnl	23	8	famotidine	famotidine	NN
cord-308293-8y2iaqnl	23	9	formulations	formulation	NNS
cord-308293-8y2iaqnl	23	10	such	such	JJ
cord-308293-8y2iaqnl	23	11	as	as	IN
cord-308293-8y2iaqnl	23	12	Pepcid	Pepcid	NNP
cord-308293-8y2iaqnl	23	13	complete	complete	NN
cord-308293-8y2iaqnl	23	14	®	®	VBP
cord-308293-8y2iaqnl	23	15	commonly	commonly	RB
cord-308293-8y2iaqnl	23	16	contain	contain	VB
cord-308293-8y2iaqnl	23	17	800	800	CD
cord-308293-8y2iaqnl	23	18	mg	mg	NN
cord-308293-8y2iaqnl	23	19	calcium	calcium	NN
cord-308293-8y2iaqnl	23	20	carbonate	carbonate	NN
cord-308293-8y2iaqnl	23	21	per	per	IN
cord-308293-8y2iaqnl	23	22	10	10	CD
cord-308293-8y2iaqnl	23	23	mg	mg	NNP
cord-308293-8y2iaqnl	23	24	famotidine	famotidine	NN
cord-308293-8y2iaqnl	23	25	.	.	.
cord-308293-8y2iaqnl	24	1	The	the	DT
cord-308293-8y2iaqnl	24	2	answers	answer	NNS
cord-308293-8y2iaqnl	24	3	to	to	IN
cord-308293-8y2iaqnl	24	4	these	these	DT
cord-308293-8y2iaqnl	24	5	questions	question	NNS
cord-308293-8y2iaqnl	24	6	are	be	VBP
cord-308293-8y2iaqnl	24	7	pathophysiologically	pathophysiologically	RB
cord-308293-8y2iaqnl	24	8	relevant	relevant	JJ
cord-308293-8y2iaqnl	24	9	as	as	IN
cord-308293-8y2iaqnl	24	10	we	-PRON-	PRP
cord-308293-8y2iaqnl	24	11	have	have	VBP
cord-308293-8y2iaqnl	24	12	recently	recently	RB
cord-308293-8y2iaqnl	24	13	published	publish	VBN
cord-308293-8y2iaqnl	24	14	a	a	DT
cord-308293-8y2iaqnl	24	15	report	report	NN
cord-308293-8y2iaqnl	24	16	in	in	IN
cord-308293-8y2iaqnl	24	17	your	-PRON-	PRP$
cord-308293-8y2iaqnl	24	18	journal	journal	NN
cord-308293-8y2iaqnl	24	19	4	4	CD
cord-308293-8y2iaqnl	24	20	,	,	,
cord-308293-8y2iaqnl	24	21	suggesting	suggest	VBG
cord-308293-8y2iaqnl	24	22	that	that	IN
cord-308293-8y2iaqnl	24	23	the	the	DT
cord-308293-8y2iaqnl	24	24	hypocalcemia	hypocalcemia	NN
cord-308293-8y2iaqnl	24	25	commonly	commonly	RB
cord-308293-8y2iaqnl	24	26	seen	see	VBN
cord-308293-8y2iaqnl	24	27	in	in	IN
cord-308293-8y2iaqnl	24	28	severe	severe	JJ
cord-308293-8y2iaqnl	24	29	COVID-19	covid-19	JJ
cord-308293-8y2iaqnl	24	30	disease	disease	NN
cord-308293-8y2iaqnl	24	31	is	be	VBZ
cord-308293-8y2iaqnl	24	32	prognostically	prognostically	RB
cord-308293-8y2iaqnl	24	33	and	and	CC
cord-308293-8y2iaqnl	24	34	mechanistically	mechanistically	RB
cord-308293-8y2iaqnl	24	35	relevant	relevant	JJ
cord-308293-8y2iaqnl	24	36	to	to	IN
cord-308293-8y2iaqnl	24	37	disease	disease	NN
cord-308293-8y2iaqnl	24	38	outcomes	outcome	NNS
cord-308293-8y2iaqnl	24	39	.	.	.
cord-308293-8y2iaqnl	25	1	We	-PRON-	PRP
cord-308293-8y2iaqnl	25	2	proposed	propose	VBD
cord-308293-8y2iaqnl	25	3	that	that	IN
cord-308293-8y2iaqnl	25	4	calcium	calcium	NN
cord-308293-8y2iaqnl	25	5	supplementation	supplementation	NN
cord-308293-8y2iaqnl	25	6	early	early	RB
cord-308293-8y2iaqnl	25	7	in	in	IN
cord-308293-8y2iaqnl	25	8	the	the	DT
cord-308293-8y2iaqnl	25	9	disease	disease	NN
cord-308293-8y2iaqnl	25	10	can	can	MD
cord-308293-8y2iaqnl	25	11	,	,	,
cord-308293-8y2iaqnl	25	12	by	by	IN
cord-308293-8y2iaqnl	25	13	interacting	interact	VBG
cord-308293-8y2iaqnl	25	14	with	with	IN
cord-308293-8y2iaqnl	25	15	fatty	fatty	JJ
cord-308293-8y2iaqnl	25	16	acids	acid	NNS
cord-308293-8y2iaqnl	25	17	,	,	,
cord-308293-8y2iaqnl	25	18	reduce	reduce	VB
cord-308293-8y2iaqnl	25	19	the	the	DT
cord-308293-8y2iaqnl	25	20	lipotoxicity	lipotoxicity	NN
cord-308293-8y2iaqnl	25	21	which	which	WDT
cord-308293-8y2iaqnl	25	22	may	may	MD
cord-308293-8y2iaqnl	25	23	exacerbate	exacerbate	VB
cord-308293-8y2iaqnl	25	24	the	the	DT
cord-308293-8y2iaqnl	25	25	disease	disease	NN
cord-308293-8y2iaqnl	25	26	,	,	,
cord-308293-8y2iaqnl	25	27	and	and	CC
cord-308293-8y2iaqnl	25	28	result	result	VB
cord-308293-8y2iaqnl	25	29	in	in	IN
cord-308293-8y2iaqnl	25	30	organ	organ	NN
cord-308293-8y2iaqnl	25	31	failure	failure	NN
cord-308293-8y2iaqnl	25	32	.	.	.
cord-308293-8y2iaqnl	26	1	Using	use	VBG
cord-308293-8y2iaqnl	26	2	in	in	IN
cord-308293-8y2iaqnl	26	3	silico	silico	NN
cord-308293-8y2iaqnl	26	4	molecular	molecular	JJ
cord-308293-8y2iaqnl	26	5	docking	docking	NN
cord-308293-8y2iaqnl	26	6	screens	screen	NNS
cord-308293-8y2iaqnl	26	7	,	,	,
cord-308293-8y2iaqnl	26	8	famotidine	famotidine	NNP
cord-308293-8y2iaqnl	26	9	has	have	VBZ
cord-308293-8y2iaqnl	26	10	been	be	VBN
cord-308293-8y2iaqnl	26	11	characterized	characterize	VBN
cord-308293-8y2iaqnl	26	12	as	as	IN
cord-308293-8y2iaqnl	26	13	potentially	potentially	RB
cord-308293-8y2iaqnl	26	14	being	be	VBG
cord-308293-8y2iaqnl	26	15	able	able	JJ
cord-308293-8y2iaqnl	26	16	to	to	TO
cord-308293-8y2iaqnl	26	17	bind	bind	VB
cord-308293-8y2iaqnl	26	18	papain	papain	NN
cord-308293-8y2iaqnl	26	19	-	-	HYPH
cord-308293-8y2iaqnl	26	20	like	like	JJ
cord-308293-8y2iaqnl	26	21	protease	protease	NN
cord-308293-8y2iaqnl	26	22	(	(	-LRB-
cord-308293-8y2iaqnl	26	23	PLpro	PLpro	NNP
cord-308293-8y2iaqnl	26	24	)	)	-RRB-
cord-308293-8y2iaqnl	26	25	and	and	CC
cord-308293-8y2iaqnl	26	26	3	3	CD
cord-308293-8y2iaqnl	26	27	chymotrypsin	chymotrypsin	VB
cord-308293-8y2iaqnl	26	28	-	-	HYPH
cord-308293-8y2iaqnl	26	29	like	like	JJ
cord-308293-8y2iaqnl	26	30	protease	protease	NN
cord-308293-8y2iaqnl	26	31	(	(	-LRB-
cord-308293-8y2iaqnl	26	32	Mpro	Mpro	NNP
cord-308293-8y2iaqnl	26	33	)	)	-RRB-
cord-308293-8y2iaqnl	26	34	of	of	IN
cord-308293-8y2iaqnl	26	35	SARS	SARS	NNP
cord-308293-8y2iaqnl	26	36	-	-	HYPH
cord-308293-8y2iaqnl	26	37	CoV-2	CoV-2	NNP
cord-308293-8y2iaqnl	26	38	2	2	CD
cord-308293-8y2iaqnl	26	39	5	5	CD
cord-308293-8y2iaqnl	26	40	.	.	.
cord-308293-8y2iaqnl	27	1	To	to	TO
cord-308293-8y2iaqnl	27	2	explore	explore	VB
cord-308293-8y2iaqnl	27	3	this	this	DT
cord-308293-8y2iaqnl	27	4	further	further	RB
cord-308293-8y2iaqnl	27	5	,	,	,
cord-308293-8y2iaqnl	27	6	we	-PRON-	PRP
cord-308293-8y2iaqnl	27	7	downloaded	download	VBD
cord-308293-8y2iaqnl	27	8	crystal	crystal	NN
cord-308293-8y2iaqnl	27	9	structures	structure	NNS
cord-308293-8y2iaqnl	27	10	of	of	IN
cord-308293-8y2iaqnl	27	11	PLpro	PLpro	NNP
cord-308293-8y2iaqnl	27	12	and	and	CC
cord-308293-8y2iaqnl	27	13	Mpro	Mpro	NNP
cord-308293-8y2iaqnl	27	14	from	from	IN
cord-308293-8y2iaqnl	27	15	RCSB.org	RCSB.org	NNP
cord-308293-8y2iaqnl	27	16	(	(	-LRB-
cord-308293-8y2iaqnl	27	17	PDB	PDB	NNP
cord-308293-8y2iaqnl	27	18	IDs	id	NNS
cord-308293-8y2iaqnl	27	19	6WX4	6wx4	CD
cord-308293-8y2iaqnl	27	20	and	and	CC
cord-308293-8y2iaqnl	27	21	6LU7	6lu7	CD
cord-308293-8y2iaqnl	27	22	,	,	,
cord-308293-8y2iaqnl	27	23	respectively	respectively	RB
cord-308293-8y2iaqnl	27	24	)	)	-RRB-
cord-308293-8y2iaqnl	27	25	and	and	CC
cord-308293-8y2iaqnl	27	26	imported	import	VBD
cord-308293-8y2iaqnl	27	27	these	these	DT
cord-308293-8y2iaqnl	27	28	to	to	IN
cord-308293-8y2iaqnl	27	29	Schrodinger	Schrodinger	NNP
cord-308293-8y2iaqnl	27	30	Maestro	Maestro	NNP
cord-308293-8y2iaqnl	27	31	.	.	.
cord-308293-8y2iaqnl	28	1	The	the	DT
cord-308293-8y2iaqnl	28	2	structures	structure	NNS
cord-308293-8y2iaqnl	28	3	were	be	VBD
cord-308293-8y2iaqnl	28	4	prepared	prepare	VBN
cord-308293-8y2iaqnl	28	5	for	for	IN
cord-308293-8y2iaqnl	28	6	docking	docking	NN
cord-308293-8y2iaqnl	28	7	,	,	,
cord-308293-8y2iaqnl	28	8	and	and	CC
cord-308293-8y2iaqnl	28	9	famotidine	famotidine	NN
cord-308293-8y2iaqnl	28	10	was	be	VBD
cord-308293-8y2iaqnl	28	11	docked	dock	VBN
cord-308293-8y2iaqnl	28	12	to	to	IN
cord-308293-8y2iaqnl	28	13	both	both	DT
cord-308293-8y2iaqnl	28	14	proteases	protease	NNS
cord-308293-8y2iaqnl	28	15	using	use	VBG
cord-308293-8y2iaqnl	28	16	the	the	DT
cord-308293-8y2iaqnl	28	17	XP	XP	NNP
cord-308293-8y2iaqnl	28	18	docking	docking	NN
cord-308293-8y2iaqnl	28	19	protocol	protocol	NN
cord-308293-8y2iaqnl	28	20	.	.	.
cord-308293-8y2iaqnl	29	1	Famotidine	Famotidine	NNP
cord-308293-8y2iaqnl	29	2	was	be	VBD
cord-308293-8y2iaqnl	29	3	found	find	VBN
cord-308293-8y2iaqnl	29	4	to	to	TO
cord-308293-8y2iaqnl	29	5	dock	dock	VB
cord-308293-8y2iaqnl	29	6	to	to	IN
cord-308293-8y2iaqnl	29	7	PLpro	PLpro	NNP
cord-308293-8y2iaqnl	29	8	with	with	IN
cord-308293-8y2iaqnl	29	9	a	a	DT
cord-308293-8y2iaqnl	29	10	GlideScore	GlideScore	NNP
cord-308293-8y2iaqnl	29	11	of	of	IN
cord-308293-8y2iaqnl	29	12	-6.86	-6.86	:
cord-308293-8y2iaqnl	29	13	kcal	kcal	NNP
cord-308293-8y2iaqnl	29	14	/	/	SYM
cord-308293-8y2iaqnl	29	15	mol	mol	NN
cord-308293-8y2iaqnl	29	16	and	and	CC
cord-308293-8y2iaqnl	29	17	to	to	IN
cord-308293-8y2iaqnl	29	18	Mpro	Mpro	NNP
cord-308293-8y2iaqnl	29	19	with	with	IN
cord-308293-8y2iaqnl	29	20	a	a	DT
cord-308293-8y2iaqnl	29	21	GlideScore	GlideScore	NNP
cord-308293-8y2iaqnl	29	22	of	of	IN
cord-308293-8y2iaqnl	29	23	-4.05	-4.05	CD
cord-308293-8y2iaqnl	29	24	kcal	kcal	NNP
cord-308293-8y2iaqnl	29	25	/	/	SYM
cord-308293-8y2iaqnl	29	26	mol	mol	NN
cord-308293-8y2iaqnl	29	27	.	.	.
cord-308293-8y2iaqnl	30	1	This	this	DT
cord-308293-8y2iaqnl	30	2	represents	represent	VBZ
cord-308293-8y2iaqnl	30	3	weak	weak	JJ
cord-308293-8y2iaqnl	30	4	,	,	,
cord-308293-8y2iaqnl	30	5	nonspecific	nonspecific	JJ
cord-308293-8y2iaqnl	30	6	binding	binding	NN
cord-308293-8y2iaqnl	30	7	of	of	IN
cord-308293-8y2iaqnl	30	8	famotidine	famotidine	NN
cord-308293-8y2iaqnl	30	9	to	to	IN
cord-308293-8y2iaqnl	30	10	both	both	DT
cord-308293-8y2iaqnl	30	11	PLpro	PLpro	NNP
cord-308293-8y2iaqnl	30	12	and	and	CC
cord-308293-8y2iaqnl	30	13	Mpro	Mpro	NNP
cord-308293-8y2iaqnl	30	14	,	,	,
cord-308293-8y2iaqnl	30	15	and	and	CC
cord-308293-8y2iaqnl	30	16	is	be	VBZ
cord-308293-8y2iaqnl	30	17	in	in	IN
cord-308293-8y2iaqnl	30	18	contradiction	contradiction	NN
cord-308293-8y2iaqnl	30	19	to	to	IN
cord-308293-8y2iaqnl	30	20	previous	previous	JJ
cord-308293-8y2iaqnl	30	21	molecular	molecular	JJ
cord-308293-8y2iaqnl	30	22	docking	docking	NN
cord-308293-8y2iaqnl	30	23	studies	study	NNS
cord-308293-8y2iaqnl	30	24	.	.	.
cord-308293-8y2iaqnl	31	1	Recently	recently	RB
cord-308293-8y2iaqnl	31	2	,	,	,
cord-308293-8y2iaqnl	31	3	in	in	IN
cord-308293-8y2iaqnl	31	4	vitro	vitro	FW
cord-308293-8y2iaqnl	31	5	experiments	experiment	NNS
cord-308293-8y2iaqnl	31	6	have	have	VBP
cord-308293-8y2iaqnl	31	7	shown	show	VBN
cord-308293-8y2iaqnl	31	8	that	that	IN
cord-308293-8y2iaqnl	31	9	famotidine	famotidine	NN
cord-308293-8y2iaqnl	31	10	DOES	do	VBZ
cord-308293-8y2iaqnl	31	11	NOT	not	RB
cord-308293-8y2iaqnl	31	12	inhibit	inhibit	VB
cord-308293-8y2iaqnl	31	13	PLpro	PLpro	NNP
cord-308293-8y2iaqnl	31	14	or	or	CC
cord-308293-8y2iaqnl	31	15	Mpro	Mpro	NNP
cord-308293-8y2iaqnl	31	16	,	,	,
cord-308293-8y2iaqnl	31	17	and	and	CC
cord-308293-8y2iaqnl	31	18	it	-PRON-	PRP
cord-308293-8y2iaqnl	31	19	does	do	VBZ
cord-308293-8y2iaqnl	31	20	not	not	RB
cord-308293-8y2iaqnl	31	21	directly	directly	RB
cord-308293-8y2iaqnl	31	22	inhibit	inhibit	VB
cord-308293-8y2iaqnl	31	23	SARS	SARS	NNP
cord-308293-8y2iaqnl	31	24	-	-	HYPH
cord-308293-8y2iaqnl	31	25	CoV-2	CoV-2	NNP
cord-308293-8y2iaqnl	31	26	infection	infection	NN
cord-308293-8y2iaqnl	31	27	6	6	CD
cord-308293-8y2iaqnl	31	28	7	7	CD
cord-308293-8y2iaqnl	31	29	,	,	,
cord-308293-8y2iaqnl	31	30	supporting	support	VBG
cord-308293-8y2iaqnl	31	31	our	-PRON-	PRP$
cord-308293-8y2iaqnl	31	32	molecular	molecular	JJ
cord-308293-8y2iaqnl	31	33	docking	docking	NN
cord-308293-8y2iaqnl	31	34	data	datum	NNS
cord-308293-8y2iaqnl	31	35	that	that	WDT
cord-308293-8y2iaqnl	31	36	famotidine	famotidine	NNP
cord-308293-8y2iaqnl	31	37	does	do	VBZ
cord-308293-8y2iaqnl	31	38	not	not	RB
cord-308293-8y2iaqnl	31	39	bind	bind	VB
cord-308293-8y2iaqnl	31	40	to	to	IN
cord-308293-8y2iaqnl	31	41	either	either	DT
cord-308293-8y2iaqnl	31	42	protease	protease	NN
cord-308293-8y2iaqnl	31	43	.	.	.
cord-308293-8y2iaqnl	32	1	It	-PRON-	PRP
cord-308293-8y2iaqnl	32	2	has	have	VBZ
cord-308293-8y2iaqnl	32	3	been	be	VBN
cord-308293-8y2iaqnl	32	4	hypothesized	hypothesize	VBN
cord-308293-8y2iaqnl	32	5	that	that	IN
cord-308293-8y2iaqnl	32	6	famotidine	famotidine	NNP
cord-308293-8y2iaqnl	32	7	could	could	MD
cord-308293-8y2iaqnl	32	8	indirectly	indirectly	RB
cord-308293-8y2iaqnl	32	9	treat	treat	VB
cord-308293-8y2iaqnl	32	10	COVID-19	COVID-19	NNP
cord-308293-8y2iaqnl	32	11	through	through	IN
cord-308293-8y2iaqnl	32	12	antagonism	antagonism	NN
cord-308293-8y2iaqnl	32	13	or	or	CC
cord-308293-8y2iaqnl	32	14	inverse	inverse	JJ
cord-308293-8y2iaqnl	32	15	agonism	agonism	NN
cord-308293-8y2iaqnl	32	16	of	of	IN
cord-308293-8y2iaqnl	32	17	histamine	histamine	NN
cord-308293-8y2iaqnl	32	18	signaling	signal	VBG
cord-308293-8y2iaqnl	32	19	as	as	IN
cord-308293-8y2iaqnl	32	20	a	a	DT
cord-308293-8y2iaqnl	32	21	result	result	NN
cord-308293-8y2iaqnl	32	22	of	of	IN
cord-308293-8y2iaqnl	32	23	binding	bind	VBG
cord-308293-8y2iaqnl	32	24	to	to	IN
cord-308293-8y2iaqnl	32	25	the	the	DT
cord-308293-8y2iaqnl	32	26	H2	H2	NNP
cord-308293-8y2iaqnl	32	27	receptor	receptor	NN
cord-308293-8y2iaqnl	32	28	6	6	CD
cord-308293-8y2iaqnl	32	29	,	,	,
cord-308293-8y2iaqnl	32	30	but	but	CC
cord-308293-8y2iaqnl	32	31	this	this	DT
cord-308293-8y2iaqnl	32	32	has	have	VBZ
cord-308293-8y2iaqnl	32	33	yet	yet	RB
cord-308293-8y2iaqnl	32	34	to	to	TO
cord-308293-8y2iaqnl	32	35	be	be	VB
cord-308293-8y2iaqnl	32	36	rigorously	rigorously	RB
cord-308293-8y2iaqnl	32	37	tested	test	VBN
cord-308293-8y2iaqnl	32	38	.	.	.
cord-308293-8y2iaqnl	33	1	While	while	IN
cord-308293-8y2iaqnl	33	2	results	result	NNS
cord-308293-8y2iaqnl	33	3	of	of	IN
cord-308293-8y2iaqnl	33	4	the	the	DT
cord-308293-8y2iaqnl	33	5	randomized	randomized	JJ
cord-308293-8y2iaqnl	33	6	clinical	clinical	JJ
cord-308293-8y2iaqnl	33	7	trial	trial	NN
cord-308293-8y2iaqnl	33	8	on	on	IN
cord-308293-8y2iaqnl	33	9	the	the	DT
cord-308293-8y2iaqnl	33	10	benefits	benefit	NNS
cord-308293-8y2iaqnl	33	11	of	of	IN
cord-308293-8y2iaqnl	33	12	intravenous	intravenous	JJ
cord-308293-8y2iaqnl	33	13	famotidine	famotidine	NN
cord-308293-8y2iaqnl	33	14	in	in	IN
cord-308293-8y2iaqnl	33	15	treating	treat	VBG
cord-308293-8y2iaqnl	33	16	COVID-19	COVID-19	NNP
cord-308293-8y2iaqnl	33	17	(	(	-LRB-
cord-308293-8y2iaqnl	33	18	NCT04370262	NCT04370262	NNP
cord-308293-8y2iaqnl	33	19	)	)	-RRB-
cord-308293-8y2iaqnl	33	20	are	be	VBP
cord-308293-8y2iaqnl	33	21	excitedly	excitedly	RB
cord-308293-8y2iaqnl	33	22	awaited	await	VBN
cord-308293-8y2iaqnl	33	23	;	;	:
cord-308293-8y2iaqnl	33	24	the	the	DT
cord-308293-8y2iaqnl	33	25	clues	clue	NNS
cord-308293-8y2iaqnl	33	26	gained	gain	VBN
cord-308293-8y2iaqnl	33	27	by	by	IN
cord-308293-8y2iaqnl	33	28	the	the	DT
cord-308293-8y2iaqnl	33	29	studies	study	NNS
cord-308293-8y2iaqnl	33	30	published	publish	VBN
cord-308293-8y2iaqnl	33	31	in	in	IN
cord-308293-8y2iaqnl	33	32	both	both	DT
cord-308293-8y2iaqnl	33	33	Gastroenterology	Gastroenterology	NNP
cord-308293-8y2iaqnl	33	34	1	1	CD
cord-308293-8y2iaqnl	33	35	4	4	CD
cord-308293-8y2iaqnl	33	36	and	and	CC
cord-308293-8y2iaqnl	33	37	Gut	Gut	NNP
cord-308293-8y2iaqnl	33	38	3	3	CD
cord-308293-8y2iaqnl	33	39	,	,	,
cord-308293-8y2iaqnl	33	40	give	give	VB
cord-308293-8y2iaqnl	33	41	hope	hope	NN
cord-308293-8y2iaqnl	33	42	that	that	IN
cord-308293-8y2iaqnl	33	43	COVID-19	COVID-19	NNP
cord-308293-8y2iaqnl	33	44	could	could	MD
cord-308293-8y2iaqnl	33	45	be	be	VB
cord-308293-8y2iaqnl	33	46	combated	combat	VBN
cord-308293-8y2iaqnl	33	47	by	by	IN
cord-308293-8y2iaqnl	33	48	delving	delve	VBG
cord-308293-8y2iaqnl	33	49	deeper	deeply	RBR
cord-308293-8y2iaqnl	33	50	into	into	IN
cord-308293-8y2iaqnl	33	51	,	,	,
cord-308293-8y2iaqnl	33	52	and	and	CC
cord-308293-8y2iaqnl	33	53	understanding	understand	VBG
cord-308293-8y2iaqnl	33	54	the	the	DT
cord-308293-8y2iaqnl	33	55	mechanistic	mechanistic	JJ
cord-308293-8y2iaqnl	33	56	basis	basis	NN
cord-308293-8y2iaqnl	33	57	of	of	IN
cord-308293-8y2iaqnl	33	58	what	what	WP
cord-308293-8y2iaqnl	33	59	was	be	VBD
cord-308293-8y2iaqnl	33	60	observed	observe	VBN
cord-308293-8y2iaqnl	33	61	.	.	.
cord-308293-8y2iaqnl	34	1	Famotidine	Famotidine	NNP
cord-308293-8y2iaqnl	34	2	Use	Use	NNP
cord-308293-8y2iaqnl	34	3	is	be	VBZ
cord-308293-8y2iaqnl	34	4	Associated	associate	VBN
cord-308293-8y2iaqnl	34	5	with	with	IN
cord-308293-8y2iaqnl	34	6	Improved	Improved	NNP
cord-308293-8y2iaqnl	34	7	Clinical	Clinical	NNP
cord-308293-8y2iaqnl	34	8	Outcomes	Outcomes	NNPS
cord-308293-8y2iaqnl	34	9	in	in	IN
cord-308293-8y2iaqnl	34	10	Hospitalized	Hospitalized	NNP
cord-308293-8y2iaqnl	34	11	COVID-19	COVID-19	NNP
cord-308293-8y2iaqnl	34	12	Patients	patient	NNS
cord-308293-8y2iaqnl	34	13	:	:	:
cord-308293-8y2iaqnl	35	1	A	a	DT
cord-308293-8y2iaqnl	36	1	Propensity	propensity	NN
cord-308293-8y2iaqnl	36	2	Score	Score	NNP
cord-308293-8y2iaqnl	36	3	Matched	match	VBD
cord-308293-8y2iaqnl	36	4	Retrospective	Retrospective	NNP
cord-308293-8y2iaqnl	36	5	Cohort	Cohort	NNP
cord-308293-8y2iaqnl	36	6	Study	Study	NNP
cord-308293-8y2iaqnl	36	7	Analysis	Analysis	NNP
cord-308293-8y2iaqnl	36	8	of	of	IN
cord-308293-8y2iaqnl	36	9	therapeutic	therapeutic	JJ
cord-308293-8y2iaqnl	36	10	targets	target	NNS
cord-308293-8y2iaqnl	36	11	for	for	IN
cord-308293-8y2iaqnl	36	12	SARS	SARS	NNP
cord-308293-8y2iaqnl	36	13	-	-	HYPH
cord-308293-8y2iaqnl	36	14	CoV-2	CoV-2	NNP
cord-308293-8y2iaqnl	36	15	and	and	CC
cord-308293-8y2iaqnl	36	16	discovery	discovery	NN
cord-308293-8y2iaqnl	36	17	of	of	IN
cord-308293-8y2iaqnl	36	18	potential	potential	JJ
cord-308293-8y2iaqnl	36	19	drugs	drug	NNS
cord-308293-8y2iaqnl	36	20	by	by	IN
cord-308293-8y2iaqnl	36	21	computational	computational	JJ
cord-308293-8y2iaqnl	36	22	methods	method	NNS
cord-308293-8y2iaqnl	37	1	Famotidine	Famotidine	NNP
cord-308293-8y2iaqnl	37	2	use	use	NN
cord-308293-8y2iaqnl	37	3	and	and	CC
cord-308293-8y2iaqnl	37	4	quantitative	quantitative	JJ
cord-308293-8y2iaqnl	37	5	symptom	symptom	NN
cord-308293-8y2iaqnl	37	6	tracking	tracking	NN
cord-308293-8y2iaqnl	37	7	for	for	IN
cord-308293-8y2iaqnl	37	8	COVID-19	COVID-19	NNP
cord-308293-8y2iaqnl	37	9	in	in	IN
cord-308293-8y2iaqnl	37	10	non	non	JJ
cord-308293-8y2iaqnl	37	11	-	-	JJ
cord-308293-8y2iaqnl	37	12	hospitalised	hospitalised	JJ
cord-308293-8y2iaqnl	37	13	patients	patient	NNS
cord-308293-8y2iaqnl	37	14	:	:	:
cord-308293-8y2iaqnl	37	15	a	a	DT
cord-308293-8y2iaqnl	37	16	case	case	NN
cord-308293-8y2iaqnl	37	17	series	series	NN
cord-308293-8y2iaqnl	37	18	Mortality	mortality	NN
cord-308293-8y2iaqnl	37	19	from	from	IN
cord-308293-8y2iaqnl	37	20	Covid-19	Covid-19	NNP
cord-308293-8y2iaqnl	37	21	Increases	Increases	NNPS
cord-308293-8y2iaqnl	37	22	with	with	IN
cord-308293-8y2iaqnl	37	23	Unsaturated	Unsaturated	NNP
cord-308293-8y2iaqnl	37	24	Fat	Fat	NNP
cord-308293-8y2iaqnl	37	25	,	,	,
cord-308293-8y2iaqnl	37	26	and	and	CC
cord-308293-8y2iaqnl	38	1	May	May	MD
cord-308293-8y2iaqnl	38	2	Be	be	VB
cord-308293-8y2iaqnl	38	3	Reduced	reduce	VBN
cord-308293-8y2iaqnl	38	4	by	by	IN
cord-308293-8y2iaqnl	38	5	Early	early	JJ
cord-308293-8y2iaqnl	38	6	Calcium	Calcium	NNP
cord-308293-8y2iaqnl	38	7	and	and	CC
cord-308293-8y2iaqnl	38	8	Albumin	Albumin	NNP
cord-308293-8y2iaqnl	38	9	Supplementation	Supplementation	NNP
cord-308293-8y2iaqnl	39	1	Binding	bind	VBG
cord-308293-8y2iaqnl	39	2	insight	insight	NN
cord-308293-8y2iaqnl	39	3	of	of	IN
cord-308293-8y2iaqnl	39	4	clinically	clinically	RB
cord-308293-8y2iaqnl	39	5	oriented	orient	VBN
cord-308293-8y2iaqnl	39	6	drug	drug	NN
cord-308293-8y2iaqnl	39	7	famotidine	famotidine	NN
cord-308293-8y2iaqnl	39	8	with	with	IN
cord-308293-8y2iaqnl	39	9	the	the	DT
cord-308293-8y2iaqnl	39	10	identified	identify	VBN
cord-308293-8y2iaqnl	39	11	potential	potential	JJ
cord-308293-8y2iaqnl	39	12	target	target	NN
cord-308293-8y2iaqnl	39	13	of	of	IN
cord-308293-8y2iaqnl	39	14	SARS	SARS	NNP
cord-308293-8y2iaqnl	39	15	-	-	HYPH
cord-308293-8y2iaqnl	39	16	CoV-2	CoV-2	NNP
cord-308293-8y2iaqnl	40	1	COVID-19	covid-19	LS
cord-308293-8y2iaqnl	40	2	:	:	:
cord-308293-8y2iaqnl	40	3	Famotidine	Famotidine	NNP
cord-308293-8y2iaqnl	40	4	,	,	,
cord-308293-8y2iaqnl	40	5	Histamine	histamine	NN
cord-308293-8y2iaqnl	40	6	,	,	,
cord-308293-8y2iaqnl	40	7	Mast	Mast	NNP
cord-308293-8y2iaqnl	40	8	Cells	Cells	NNPS
cord-308293-8y2iaqnl	40	9	,	,	,
cord-308293-8y2iaqnl	40	10	and	and	CC
cord-308293-8y2iaqnl	40	11	Mechanisms	Mechanisms	NNP
cord-308293-8y2iaqnl	40	12	Broad	Broad	NNP
cord-308293-8y2iaqnl	40	13	-	-	HYPH
cord-308293-8y2iaqnl	40	14	spectrum	spectrum	NN
cord-308293-8y2iaqnl	40	15	inhibition	inhibition	NN
cord-308293-8y2iaqnl	40	16	of	of	IN
cord-308293-8y2iaqnl	40	17	coronavirus	coronavirus	NN
cord-308293-8y2iaqnl	40	18	main	main	JJ
cord-308293-8y2iaqnl	40	19	and	and	CC
cord-308293-8y2iaqnl	40	20	papain	papain	NN
cord-308293-8y2iaqnl	40	21	-	-	HYPH
cord-308293-8y2iaqnl	40	22	like	like	JJ
cord-308293-8y2iaqnl	40	23	proteases	protease	NNS
cord-308293-8y2iaqnl	40	24	by	by	IN
cord-308293-8y2iaqnl	40	25	HCV	HCV	NNP
cord-308293-8y2iaqnl	40	26	drugs	drug	NNS